Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Uproleselan with Busulfan Conditioning in Pediatric AML
NCT05569512Phase 1Terminated
- Start
- Oct 2022
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of uproleselan in acute myeloid leukemia (AML). Primary endpoints: Recommend Phase 2 Dose and Dose Limiting Toxicity (DLT) Phase 1. Started Oct 2022; status: terminated.
02
Drugs
uproleselan
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05569512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05569512.